title: Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
authors.affiliation: InForMed GmbH-Outcomes Research and Health Economics, Ingolstadt, Germany. pk.schaedlich@informed.de
authors.forename: Peter K
authors.initials: PK
authors.lastname: Schädlich
authors.forename: Josef Georg
authors.initials: JG
authors.lastname: Brecht
authors.forename: Badrudin
authors.initials: B
authors.lastname: Rangoonwala
authors.forename: Eduard
authors.initials: E
authors.lastname: Huppertz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017257:Ramipril / Q000191:economics* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D017257:Ramipril